138 results on '"olaparib"'
Search Results
2. Olaparib research update: mechanism, structure and clinical trials
3. A combination formulation of TPGS micelles loaded with paclitaxel and olaparib and a pH-thermosensitive hydrogel for treating peritoneal metastasis and drug-resistant ovarian cancer
4. Olaparib-associated toxicity in cancer patients: a systematic review and meta-analysis
5. First evidence of olaparib maintenance therapy in patients with newly diagnosed homologous recombination deficient positive/BRCA wild-type ovarian cancer: real-world multicenter study
6. Olaparib synergically exacerbates the radiation-induced intestinal apoptosis in mice
7. Olaparib-Induced Cutaneous Vasculitis in a Patient with Ovarian Cancer: A Case Report and Literature Review
8. Regorafenib induces DNA damage and enhances PARP inhibitor efficacy in pancreatic ductal carcinoma
9. Patterns of genomic instability in > 2000 patients with ovarian cancer across six clinical trials evaluating olaparib
10. Olaparib enhancing radiosensitization and anti-metastatic effect of oral cancer by targeting IL-17A signal
11. Inhibiting ADAM17 enhances the efficacy of olaparib in ovarian cancer spheroids
12. Celastrol attenuates the invasion and migration and augments the anticancer effects of olaparib in prostate cancer
13. Low-dose abiraterone plus Olaparib as a late-line treatment for mCRPC patients without BRCA1/2 mutations: a multicenter retrospective pilot study
14. Real-world data on the prevalence of BRCA1/2 and HRR gene mutations in patients with primary and metastatic castration resistant prostate cancer
15. Conversion surgery for BRCA-mutated pancreatic ductal adenocarcinoma with liver metastasis treated with platinum-based chemotherapy followed by olaparib
16. Exploratory biomarker analysis in the phase III L-MOCA study of olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer
17. PARP inhibitor era in ovarian cancer treatment: a systematic review and meta-analysis of randomized controlled trials
18. Case report of penile squamous cell carcinoma continuous treatment with BRCA2 mutation
19. Auger emitter in combination with Olaparib suppresses tumor growth via promoting antitumor immune responses in pancreatic cancer
20. ATF3-induced activation of NF-κB pathway results in acquired PARP inhibitor resistance in pancreatic adenocarcinoma
21. Development and Characterization of Olaparib-Loaded Solid Self-Nanoemulsifying Drug Delivery System (S-SNEDDS) for Pharmaceutical Applications
22. Post(neo)adjuvante Therapiekonzepte – Möglichkeiten der Individualisierung
23. Addressing Residual Disease in HER2-Positive and Triple-Negative Breast Cancer: What Is Next?
24. Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY
25. Olaparib enhances sensitization of BRCA-proficient breast cancer cells to x-rays and protons
26. Bidirectional pharmacokinetic drug interactions between olaparib and metformin
27. Kombinationstherapie mit Inhibitoren der Poly(Adenosindiphosphat-Ribose)-Polymerasen (PARPi) und des Androgenrezeptorsignalweges (ARPi) beim metastasierten kastrationsrefraktären Prostatakarzinom
28. Triggering pyroptosis enhances the antitumor efficacy of PARP inhibitors in prostate cancer
29. Elucidating the Therapeutic Utility of Olaparib in Sulfatide-Induced Human Astrocyte Toxicity and Neuroinflammation
30. Anticancer Effect of Active Component of Astragalus Membranaceus Combined with Olaparib on Ovarian Cancer Predicted by Network-Based Pharmacology
31. Olaparib Attenuates Demyelination and Neuroinflammation in an Organotypic Slice Culture Model of Metachromatic Leukodystrophy
32. Apatinib combined with olaparib induces ferroptosis via a p53-dependent manner in ovarian cancer
33. PET imaging of PARP expression using 68Ga-labelled inhibitors
34. Clinical efficacy of PARP inhibitors in breast cancer
35. Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial
36. First report for the electrochemical determination and proposed mechanism of poly(ADP ribose) polymerase inhibitor and new smart anticancer drug olaparib
37. Combination of Resveratrol and PARP inhibitor Olaparib efficiently deregulates homologous recombination repair pathway in breast cancer cells through inhibition of TIP60-mediated chromatin relaxation
38. Synergistic lethality in chronic myeloid leukemia – targeting oxidative phosphorylation and unfolded protein response effectively complements tyrosine kinase inhibitor treatment
39. Modulation of SLFN11 induces changes in DNA Damage response in breast cancer
40. Drug-induced interstitial lung disease caused by olaparib: three case reports and review of the Japanese Adverse Drug Event Report database and literature
41. PARP1 negatively regulates transcription of BLM through its interaction with HSP90AB1 in prostate cancer
42. Racial differences in RAD51 expression are regulated by miRNA-214-5P and its inhibition synergizes with olaparib in triple-negative breast cancer
43. A Case of Recurrent Ovarian Cancer with Renal Dysfunction Associated with the Use of Olaparib
44. Incidence and risk of hypertension associated with PARP inhibitors in cancer patients: a systematic review and meta-analysis
45. Exposure–Response Analyses of Olaparib in Real-Life Patients with Ovarian Cancer
46. Effect of Usnic Acid-Derived Tyrosyl-DNA Phosphodiesterase 1 Inhibitor Used as Monotherapy or in Combination with Olaparib on Transplanted Tumors In Vivo
47. Olaparib in an ovarian cancer patient with end-stage renal disease and hemodialysis
48. Interstitial pneumonia after regression by olaparib for neuroendocrine prostate cancer with BRCA1 mutation: a case report
49. Pathologic complete response following FOLFIRINOX and olaparib treatment for hepatic metastasized pancreatic ductal adenocarcinoma with a germline BRCA mutation
50. Resistance to Poly (ADP-Ribose) Polymerase Inhibitors (PARPi): Mechanisms and Potential to Reverse
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.